Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/177059
Title: | Genetically determined telomere length and multiple myeloma risk and outcome |
Author: | Giaccherini, Matteo Macauda, Angelica Orciuolo, Enrico Rymko, Marcin Gruenpeter, Karolina Dumontet, Charles Raźny, Malgorzata Moreno Aguado, Víctor Buda, Gabriele Beider, Katia Varkonyi, Judit Avet-Loiseau, Hervé Martínez López, Joaquín Marques, Herlander Watek, Marzena Sarasquete, Maria Eugenia Andersen, Vibeke Karlin, Lionel Suska, Anna Kruszewski, Marcin Abildgaard, Niels Dudziński, Marek Butrym, Aleksandra Nagler, Arnold Vangsted, Annette Juul Kadar, Katalin Waldemar, Tomczak Jamroziak, Krzysztof Jacobsen, Svend Erik Hove Ebbesen, Lene Hyldahl Taszner, Michał Mazur, Grzegorz Lesueur, Fabienne Pelosini, Matteo García Sanz, Ramón Jurczyszyn, Artur Demangel, Delphine Reis, Rui Manuel Iskierka-Jażdżewska, Elżbieta Markiewicz, Miroslaw Gemignani, Federica Subocz, Edyta Zawirska, Daria Druzd-Sitek, Agnieszka Stępień, Anna Alonso Aguado, Maria Henar Sainz, Juan Canzian, Federico Campa, Daniele |
Keywords: | Mieloma múltiple Telòmer Multiple myeloma Telomere |
Issue Date: | 1-Apr-2021 |
Publisher: | Springer Nature |
Abstract: | Telomeres are involved in processes like cellular growth, chromosomal stability, and proper segregation to daughter cells. Telomere length measured in leukocytes (LTL) has been investigated in different cancer types, including multiple myeloma (MM). However, LTL measurement is prone to heterogeneity due to sample handling and study design (retrospective vs. prospective). LTL is genetically determined; genome-wide association studies identified 11 SNPs that, combined in a score, can be used as a genetic instrument to measure LTL and evaluate its association with MM risk. This approach has been already successfully attempted in various cancer types but never in MM. We tested the "teloscore" in 2407 MM patients and 1741 controls from the International Multiple Myeloma rESEarch (IMMeNSE) consortium. We observed an increased risk for longer genetically determined telomere length (gdTL) (OR = 1.69; 95% CI 1.36-2.11; P = 2.97 x 10(-6) for highest vs. lowest quintile of the score). Furthermore, in a subset of 1376 MM patients we tested the relationship between the teloscore and MM patients survival, observing a better prognosis for longer gdTL compared with shorter gdTL (HR = 0.93; 95% CI 0.86-0.99; P = 0.049). In conclusion, we report convincing evidence that longer gdTL is a risk marker for MM risk, and that it is potentially involved in increasing MM survival. |
Note: | Reproducció del document publicat a: https://doi.org/10.1038/s41408-021-00462-y |
It is part of: | Blood Cancer Journal, 2021, vol. 11 |
URI: | http://hdl.handle.net/2445/177059 |
Related resource: | https://doi.org/10.1038/s41408-021-00462-y |
Appears in Collections: | Articles publicats en revistes (Ciències Clíniques) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
s41408-021-00462-y.pdf | 676.37 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License